Patents by Inventor Ryan A LACINSKI

Ryan A LACINSKI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Protein-loaded PLGA nanospheres
    Patent number: 12214046
    Abstract: The present disclosure provides compositions comprising protein encapsulated nanoparticles, and methods of making said compositions. In an aspect, a composition may comprise a drug delivery vector and a therapeutic substance, wherein the composition elutes at least 1.0 pg of the therapeutic substance per 100,000 particles of the drug delivery vector over a period of time under conditions of a drug delivery vector release buffer, wherein the therapeutic substance, drug delivery vector and drug delivery vector release buffer comprise a solution, wherein the solution is centrifuged and a portion stored at about 1 to 10° C., and wherein the elution of the therapeutic substance is determined by ELISA assay. This disclosure further describes a method of controlling an immunophenotype in a patient suffering from a disease which impacts the immune system.
    Type: Grant
    Filed: June 2, 2022
    Date of Patent: February 4, 2025
    Assignee: West Virginia University Board of Governors on behalf of West Virginia University
    Inventors: Brock A Lindsey, Justin E Markel, Ryan A Lacinski, Jabeen Noore
  • PROTEIN-LOADED PLGA NANOSPHERES
    Publication number: 20230070180
    Abstract: The present disclosure provides compositions comprising protein encapsulated nanoparticles, and methods of making said compositions. In an aspect, a composition may comprise a drug delivery vector and a therapeutic substance, wherein the composition elutes at least 1.0 pg of the therapeutic substance per 100,000 particles of the drug delivery vector over a period of time under conditions of a drug delivery vector release buffer, wherein the therapeutic substance, drug delivery vector and drug delivery vector release buffer comprise a solution, wherein the solution is centrifuged and a portion stored at about 1 to 10° C., and wherein the elution of the therapeutic substance is determined by ELISA assay. This disclosure further describes a method of controlling an immunophenotype in a patient suffering from a disease which impacts the immune system.
    Type: Application
    Filed: June 2, 2022
    Publication date: March 9, 2023
    Inventors: BROCK A. LINDSEY, Justin E MARKEL, Ryan A LACINSKI, Jabeen NOORE